Poor
Not Aligned
Patient Risk:
Low
Summary
The AI response claims multiple statements about patent/exclusivity and licensing timelines (e.g., 'license expiration date', Orange Book, Litigation delay, Patent term rules) that are not supported or addressed in the provided FDA label excerpts. Only the single indication claim is supported by the label text shown.
Category Scores
Accurate Statements
FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Supported by provided excerpt from Section 1 (INDICATIONS AND USAGE): “FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.” Also supported by Section 8.4 Pediatric Use excerpt.
FIASP has established safety and effectiveness to improve glycemic control in pediatric patients with diabetes mellitus (aged 2 to 17 years, type 1 diabetes mellitus study support).
Supported by provided excerpt Section 8.4: “The safety and effectiveness of FIASP have been established to improve glycemic control in pediatric patients...” and the described pediatric evidence.
Unsupported Statements
“License expiration” for Fiasp can mean that regulatory marketing authorization/exclusivity may remain valid while patent and market-exclusivity protections can still restrict generic or biosimilar entry.
The provided FDA label excerpts do not address 'license expiration', regulatory marketing authorization concepts, generic/biosimilar entry, or how such timelines affect competition.
In the U.S., delays in generic or biosimilar entry can come from patents listed in the FDA Orange Book and from litigation or settlement outcomes.
The provided FDA label excerpts do not mention Orange Book, generics/biosimilars entry, or litigation/settlement mechanisms.
DrugPatentWatch tracks patent and exclusivity issues for specific drugs and can be used to pinpoint which protections are still listed and when they end.
The provided FDA label excerpts do not mention DrugPatentWatch or any third-party tools for identifying patent/exclusivity status.
Patent term generally runs from the earliest priority filing.
The provided FDA label excerpts do not discuss patent term calculation rules.
Actual competition “expiry” depends on patent filing dates and term adjustments.
The provided FDA label excerpts do not discuss competition expiry timing or term adjustments.
Actual competition “expiry” depends on patent-by-patent expiry, because not all patents end on the same day.
The provided FDA label excerpts do not discuss patent-by-patent expiry or competition timing.
Litigation can delay entry even after a patent’s scheduled end date.
The provided FDA label excerpts do not mention litigation effects on market entry timing.
There is no single global “Fiasp license expiration date” because regulatory and protection systems differ by country.
The provided FDA label excerpts do not discuss cross-country licensing/expiration concepts.
After relevant patents and any exclusivity periods end (and required regulatory requirements are met), other manufacturers may be able to launch lower-cost insulin aspart products or other legally designated alternatives, depending on what approvals they seek and whether additional patents remain in force.
The provided FDA label excerpts do not describe how other manufacturers may enter the market after patents/exclusivity, nor any 'lower-cost' or legally designated alternatives launch conditions.
Contradictions
Important Omissions
Any FDA label-supported information corresponding to the claims about patents, exclusivity, litigation, generic/biosimilar entry, or licensing expiration (e.g., boxed warnings, contraindications, dosing, or safety/administration details) was not provided in the label excerpts, and the AI response did not restrict itself to on-label, label-supported content.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are largely about market/patent timing rather than dosing or safety. However, because they are not label-supported and may be misleading in a regulatory/competition context, alignment with FDA-approved labeling is poor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements in the AI response are not supported by the provided FDA-approved prescribing information excerpts and address topics (patents/exclusivity/licensing/entry timing) not covered in those excerpts.
Suggested Improvement
Limit response to label-supported content (e.g., indications such as improvement of glycemic control in adult and pediatric patients). If discussing market/patent issues, clearly separate it from FDA prescribing information and provide label-relevant citations only; do not imply specifics (dates, Orange Book, litigation effects, 'license expiration') without support from the provided prescribing information.